Key Data Files for this Active Pharmaceutical Ingredient:

Drug Master Files, 21 CFR, and other industry portals Patent/Exclusivity data file Drug Approval Drug Safety Freedom of Information Federal Register pages Pharma Companies Pharmacopeial Information Preferred API Supplier (Clients Only)

FDA Approval Activities for this Drug… Atacand HCT (candesartan cilexetil - hydrochlorothiazide) Tablets, 16-12.5 and 32-12.5 mg, AstraZeneca LP NDA 21-093 9/5/00 9/11/00 9/11/00 7/30/01 Atacand (candesartan cilexetil), Tablets, 4, 8, 16, and 32 mg, AstraZeneca LP NDA 20-838/S019 4/23/03 Atacand (candesartan cilexetil), Tablets, 4, 8, 16, and 32 mg, AstraZeneca LP NDA 20-838/S017 1/22/03 1/27/03 Atacand (candesartan cilexetil), Tablets, 4, 8, 16, and 32 mg AstraZeneca LP NDA 20-838/S015 9/13/02 9/20/02 9/17/02 2/4/03 Atacand (candesartan cilexetil), Tablets, 4, 8, 16, and 32 mg AstraZeneca LP NDA 20-838/S008 6/14/00 6/6/01 Atacand (candesartan cilexetil) Tablets, 4, 8, 16, and 32 mg Astra Merck NDA 20-838 6/4/98 6/8/98 6/8/98 4/11/02 Atacand Indication: for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.   For the latest approval information, locate this drug using this index.